Alkermes
high unmet needs remain for treatment of refractory melanoma melanoma burden mucosal melanoma fifth most common type of cancer in the prevalence new cases in estimated deaths in the in due to melanoma melanoma patients with distant metastases have a year survival rate of incidence has risen faster than almost any common cancer type in the last years rare and aggressive type of melanoma occurring in mucosal membranes that is often diagnosed late due to non specific symptoms and anatomic location poor prognosis when compared with cutaneous melanoma year survival rates as low as for mucosal melanoma mucosal melanoma is largely resistant to traditional therapies response rates with chemotherapy are poor and targeted therapies such as inhibitors are usually not an option for mucosal melanoma immune inhibitors have lower response rates for mucosal melanoma than for cutaneous melanoma was recently granted orphan drug designation for mucosal melanoma epidemiology of melanoma in ward editors cutaneous melanoma etiology and therapy codon publications chapter available from codon primary mucosal melanomas a comprehensive review combatting mucosal melanoma recent advances and future perspectives melanoma published efficacy and safety of alone or in combination with in patients with mucosal melanoma a pooled analysis be eat location parle lene at years | Alkermes
Company
Deck Type
Deck date
March 2021
Slide
65 of 144
Related slides by other companies
Investor Presentation
May 2020
Investor Presentation
March 2022
Other recent decks by Alkermes
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2023 Slidebook.io